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Abstract 
Long INterspersed Element class 1 (LINE-1) elements are a type of abundant 
retrotransposons active in mammalian genomes. An average human genome contains 
~100 retrotransposition-competent LINE-1s, whose activity is influenced by the combined 
action of cellular repressors and activators. TREX1, SAMHD1 and ADAR1 are known 
LINE-1 repressors and when mutated cause the autoinflammatory disorder Aicardi-
Goutières syndrome (AGS). Mutations in RNase H2 are the most common cause of AGS 
and its activity was proposed to similarly control LINE-1 retrotransposition. It has therefore 
been suggested that increased LINE-1 activity may be the cause of aberrant innate immune 
activation in AGS. Here we establish that, contrary to expectations, RNase H2 is required 
for efficient LINE-1 retrotransposition. As RNASEH1 overexpression partially rescues the 
defect in RNase H2 null cells, we propose a model in which RNase H2 degrades the LINE-
1 RNA after reverse transcription, allowing retrotransposition to be completed. This also 
explains how LINE-1 elements can retrotranspose efficiently without their own RNase H 
activity. Our findings appear to be at odds with LINE-1 derived nucleic acids driving 
autoinflammation in AGS. 
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Introduction 
A significant proportion of most mammalian genomes consists of LINE-derived sequences, 
and the majority of these contain active LINE-1 (L1) elements. An average human genome 
contains more than 500,000 L1 copies but only 80-100 can currently mobilise (Beck et al, 
2010; Brouha et al, 2003); these are termed retrotransposition-competent L1s or RC-L1s. 
As LINE-1 retrotransposition occurs randomly throughout the human genome, insertion 
events are sporadically mutagenic and can result in an array of genetic disorders 
((Kazazian et al, 1988), reviewed in (Garcia-Perez et al, 2016; Hancks & Kazazian, 2012)). 
RC-L1s are 6-kb in length, contain an internal promoter in their 5’-UnTranslated Region 
(UTR) (Swergold, 1990), code for two intact Open Reading Frames (L1-ORF1p and L1-
ORF2p), and end in a short 3’-UTR containing a variable sized poly-A tail required for 
retrotransposition (Doucet et al, 2015; Scott et al, 1987). L1-ORF1p is an RNA binding 
protein (Khazina & Weichenrieder, 2009) with nucleic acid chaperone activity (Martin & 
Bushman, 2001); L1-ORF2p codes for a protein with both Endonuclease (EN, (Feng et al, 
1996)) and Reverse Transcriptase activities (RT, (Mathias et al, 1991), reviewed in 
(Richardson et al, 2015)). The enzymatic activities of L1-ORF1p and L1-ORF2p are strictly 
required for LINE-1 retrotransposition (Moran et al, 1996). In addition, L1-ORF2p contains 
a PCNA Interaction Protein motif (PIP) that allows interaction with PCNA (Proliferating Cell 
nuclear Antigen) and is required for efficient L1 retrotransposition (Taylor et al, 2013).  
LINE-1 retrotransposition occurs by a mechanism termed Target Primed Reverse 
Transcription (TPRT, (Luan et al, 1993)). Briefly, upon transcription and translation of a full-
length L1 mRNA (Alisch et al, 2006; Dmitriev et al, 2007; Swergold, 1990), both L1-
encoded proteins bind to their own L1 mRNA in a process termed cis-preference (Wei et 
al, 2001), generating an L1 RiboNucleoprotein Particle (L1-RNP) that is considered a 
retrotransposition intermediate. Next, L1-RNPs access the nucleus by a process that does 
not require cell division (Kubo et al, 2006; Macia et al, 2017). In the nucleus, the L1 mRNA 
is reverse transcribed and integrated in a new genomic location by TPRT (Cost et al, 2002; 
Luan et al, 1993; Piskareva et al, 2003; Piskareva & Schmatchenko, 2006). During TPRT, 
L1-ORF2p recognizes and cleaves the bottom strand of genomic DNA in a consensus 
sequence (5´TTTT/AA and variants, (Jurka, 1997)), generating a free 3´OH that is used by 
the RT activity of L1-ORF2p to prime first-strand cDNA synthesis. As a result, an L1 
RNA:cDNA hybrid covalently linked to the genome is generated. The mechanism of 
second-strand cDNA synthesis is not fully understood, but requires removal of the L1 
mRNA from the generated hybrid, which allows second strand cDNA synthesis to occur. In 
this context, there are two main classes of LINE elements: elements coding for a functional 
RNase H domain (mostly present in plants and lower eukaryotes) and elements that lack 
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this domain (most mammals, including human LINE-1s) (Malik et al, 1999; Olivares et al, 
2002; Piskareva & Schmatchenko, 2006). RNase H enzyme activity degrades the RNA 
strand of RNA:DNA heteroduplexes, and how LINE elements without a functional RNase 
H domain achieve this is currently not known. Either way, it is assumed that upon removal 
of the LINE mRNA from the hybrid, the top strand of genomic DNA is cleaved, presumably 
by L1-ORF2p, releasing a 3´OH that is then used to prime second strand cDNA synthesis, 
also presumed to be carried out by L1-ORF2p (Cost et al, 2002; Piskareva et al, 2003; 
Piskareva & Schmatchenko, 2006) (reviewed in (Richardson et al, 2015)). The result of 
TPRT is the generation of a new LINE-1 insertion, usually flanked by short Target Site 
Duplications (TSDs) and often 5’-truncated (Richardson et al, 2015).  
Due to their mutagenic potential, the host has evolved a myriad of mechanisms to control 
LINE-1 expression and retrotransposition (recently reviewed in (Garcia-Perez et al, 2016; 
Heras et al, 2014; Pizarro & Cristofari, 2016)). Some repressors of L1 activity, when 
mutated, were shown to cause rare genetic disorders, such as Ataxia Telangiectasia 
(Coufal et al, 2011) and Aicardi-Goutières syndrome (AGS, reviewed in (Volkman & 
Stetson, 2014)). AGS is a type I interferonopathy where aberrant innate immune activation 
causes type I IFN production and clinical features reminiscent of a congenital viral infection 
of the brain (Crow & Manel, 2015). AGS is caused by mutations in one of seven genes: the 
3´exonuclease TREX1 (Crow et al, 2006a), the deoxynucleoside triphosphate 
triphosphohydrolase and putative ribonuclease SAM domain and HD domain 1 (SAMHD1) 
(Rice et al, 2009), the adenosine deaminase acting on RNA 1 (ADAR1) (Rice et al, 2012), 
the dsRNA cytosolic sensor IFN-induced helicase C domain containing protein 1 (IFIH1) 
(Rice et al, 2014) and the three subunits of the ribonuclease H2 (RNase H2) endonuclease 
complex (RNASEH2A, RNASEH2B and RNASEH2C) (Crow et al, 2006b) (reviewed by 
(Crow & Manel, 2015). In most cases, the IFN response in AGS patients is likely the 
consequence of the accumulation of aberrant cytoplasmic nucleic acids that activate innate 
immune receptors. Although the nature of such immunostimulatory nucleic acids has not 
been fully characterized, retrotransposons have been proposed as a possible source 
(Volkman & Stetson, 2014). In line with this, TREX1, SAMHD1 and ADAR1 have been 
shown to inhibit the mobility of LINE-1s (Orecchini et al, 2017; Stetson et al, 2008; Zhao et 
al, 2013), and RNase H2, mutated in more than half of all known AGS patients (Crow et al, 
2015), was suggested to similarly control LINE-1 retrotransposition (Volkman & Stetson, 
2014).  
Mammalian cells have two enzymes with the ability to degrade the RNA strand of 
RNA:DNA heteroduplexes: RNase H1 and RNase H2 (reviewed by (Cerritelli & Crouch, 
2009)). RNase H1 has two isoforms, one localises to mitochondria and is essential for 
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mitochondrial DNA replication (Cerritelli et al, 2003), the second is nuclear and important 
for preventing R-loops and consequent transcription-replication conflicts (Nguyen et al, 
2017; Parajuli et al, 2017; Shen et al, 2017). RNase H2, a heterotrimeric complex, is the 
predominant nuclear enzyme responsible for RNA:DNA hybrid degradation (reviewed by 
(Reijns & Jackson, 2014)), although this may depend on cell type. RNase H2 is essential 
for genome stability, and also has the ability to cleave the 5’-phosphodiester bond of 
ribonucleotides embedded in a DNA duplex, an activity required for the removal of 
misincorporated ribonucleotides (Hiller et al, 2012; Nick McElhinny et al, 2010; Reijns et al, 
2012) in a process called ribonucleotide excision repair or RER (Sparks et al, 2012). 
Whereas the catalytic core of RNase H2 is present in the RNASEH2A subunit, all three 
subunits are required for its activity (Reijns & Jackson, 2014). The precise role for the 
accessory RNASEH2B and C subunits is not well understood, but a functional PCNA-
interacting PIP motif is found in RNASEH2B (Chon et al, 2009), directing RNase H2 activity 
to replication and repair foci (Bubeck et al, 2011; Kind et al, 2014).  
Here, we analyse the role of RNase H2 in LINE-1 retrotransposition and find that, in 
contrast to other AGS proteins, RNase H2 enzyme activity facilitates human LINE-1 
retrotransposition. In the absence of RNase H2, overexpression of RNase H1 partially 
rescues the LINE-1 retrotransposition defect. Furthermore, overexpression of wildtype 
RNase H2 or a separation of function mutant of RNase H2 that can only cleave RNA:DNA 
heteroduplexes results in increased LINE-1 retrotransposition. The requirement for RNase 
H2 appears to be specific to retroelements without their own RNase H domain, suggesting 
that cellular RNase H activity is necessary to degrade the LINE-1 RNA in the RNA:cDNA 
hybrid generated during retrotransposition. Our findings call into question the existence of 
a unifying molecular mechanism for AGS pathogenesis centred around the accumulation 
of LINE-1 nucleic acids. 
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Results 
LINE-1 retrotransposition is compromised in RNase H2 null HeLa cells 
To test the effect of RNase H2 on LINE-1 retrotransposition, we generated a panel of clonal 
HeLa RNase H2 null cell lines using CRISPR/Cas9 mediated genome editing and guide 
RNAs (gRNAs) directed to the RNASEH2A subunit (Fig 1). Individual mutant clones were 
selected based on deletions/insertions observed after PCR amplification and sequencing 
of the target locus. Loss of RNASEH2A expression and reduced levels of RNASEH2B and 
C were shown by Western analysis in knockout clones (KO, Fig 1A). Additionally, loss of 
RNase H activity in cell lysates against single embedded ribonucleotides was confirmed 
using a FRET-based fluorescent substrate release assay (Fig 1B). Finally, increased 
fragmentation of genomic DNA from KO clones after RNase H2 treatment and alkaline gel 
electrophoresis indicated the presence of large numbers of embedded ribonucleotides in 
KO clones (Fig 1C), a well-known consequence of RNase H2 deficiency (Hiller et al, 2012; 
Nick McElhinny et al, 2010; Reijns et al, 2012). For these and subsequent experiments, 
KO clones were compared to parental cells as well as CRISPR control clones (C) that 
retained significant RNase H2 activity. 
These RNase H2 null and control clones were used in a cell-based LINE-1 mobilization 
assay, which makes use of an active human LINE-1 element (L1.3, (Sassaman et al, 1997)) 
tagged with a reporter gene that can only be activated after a round of retrotransposition 
(Fig 1D and EV1A, (Moran et al, 1996)). As a reporter gene we used mblastI (Goodier et 
al, 2007; Morrish et al, 2002), which activates the Blasticidin resistant gene after 
retrotransposition (Fig 1D, plasmid JJ101/L1.3). Importantly, this assay is quantitative, and 
the resulting number of drug-resistant colonies provides a readout of retrotransposition 
activity (Goodier et al, 2007; Morrish et al, 2002). Surprisingly, LINE-1 retrotransposition 
was severely reduced in the RNase H2 null lines (n = 6 clones), with an average level of 
retrotransposition of 6.0±2.6% (mean ± SD) compared to control lines (n = 6, 94±22%; P = 
0.0022) or parental cells (set to 100%) (Fig 1E, F). As expected, control plasmids 
containing RT mutated LINE-1 (JJ101/L1.3-D702A) failed to retrotranspose in all cell lines 
(Fig 1F), whereas similar numbers of blasticidin-resistant colonies were generated for all 
cell lines after transfection with a control vector (pcDNA6.1, expressing the blasticidin 
resistant gene, Fig EV1B). Retrotransposition of an EN mutant LINE-1 (JJ101/L1.3-D205A) 
was similarly low in wild type and null cells, suggesting that DNA lesions in null cells (Reijns 
et al, 2012) are not used as integration sites by endonuclease mutant LINE-1 (Fig 1F).  
To confirm these data, we next used an L1 retrotransposition assay that activates 
expression of luciferase upon retrotransposition (Fig EV1C). This assay has two 
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advantages over the drug-resistance based assay: i) it does not require selection with 
antibiotic or generation of drug-resistant colonies, and ii) retrotransposition levels are 
measured 96 h post-transfection. This way long-term culturing is avoided, and possible 
confounding effects due to differential growth between controls and RNASEH2A-KO cell 
lines can therefore be ruled out. Using this luciferase-based assay we observed a 63% 
reduction in L1 retrotransposition in RNase H2 null cell lines (n = 3, 31±6.2%) compared to 
controls (n = 3, 84±8.3%; P = 0.0009; Fig EV1D). Furthermore, to exclude an indirect effect 
of RNase H2 deficiency on L1 expression, we performed Western blot analysis using an 
antibody against endogenous L1-ORF1p. Although there was some variation between 
clones, we confirmed that L1-ORF1p is expressed at similar levels in RNASEH2A-KO cells 
and parental cells (Fig EV1E-G). In summary, these data suggest that RNase H2 promotes 
LINE-1 retrotransposition in cultured HeLa cells.  
 
LINE-1 retrotransposition is compromised in RNase H2 null U2OS and HCT116 cells 
To determine if RNase H2 activity is required for LINE-1 mobilization in other cellular 
backgrounds, we next analysed retrotransposition in colon carcinoma (HCT116) and 
osteosarcoma (U2OS) cells. Firstly, using the same CRISPR/Cas9 strategy, we generated 
RNASEH2A-KO and control clones using HCT116 p53-/- cells. Western blotting, enzyme 
activity assays and analysis of genomic ribonucleotide incorporation confirmed absence of 
RNase H2 activity in two clonal knockout cell lines (KO, Appendix Fig S1A-C). Using the 
JJ101/L1.3-based assay, we observed significantly reduced retrotransposition in HCT116 
RNASEH2A-KO clones (n = 2, 29±8.5%) compared to controls cells (n = 4, 100±14%, P = 
0.0028) (Appendix Fig S1D, E).  
Secondly, we generated clonal RNASEH2A-KO and control lines using U2OS cells (Fig 
2A-C), which were assayed for retrotransposition alongside parental cells. Notably, and 
consistent with our data for HeLa and HCT116 p53-/- RNase H2 null cells, we observed a 
substantial reduction in LINE-1 retrotransposition in the RNASEH2A-KO lines (n = 2, 
25±9.5%) compared to parental cells (set to 100%) and a wildtype control clone (n = 2, 
94±8.2%; P = 0.016) (Fig 2D). Additional controls showed that all clones generated similar 
number of blasticidin-resistant colonies upon transfection with the control vector pcDNA6.1, 
and that an L1 RT mutant construct (L1.3-D702A) failed to retrotranspose in all U2OS 
clones tested (Fig 2D). 
In summary, LINE-1 retrotransposition is strongly reduced in multiple RNase H2 null clones 
of three different cell lines. We therefore conclude that cellular RNase H2 activity is required 
for efficient LINE-1 retrotransposition.  
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RNase H2 facilitates mobilization of non-LTR retroelements but is dispensable for 
LTR-retrotransposons and DNA-Transposons 
During LINE-1 insertion by Target Primed Reverse Transcription (TPRT), after 
endonucleolytic cleavage of genomic DNA and first strand cDNA synthesis by L1-ORF2p, 
an L1 RNA:cDNA hybrid attached to the genome is generated. The RNA in the hybrid must 
be removed prior to starting second strand cDNA synthesis. Because human L1-ORF2p 
lacks RNase H activity (Cost et al, 2002; Malik et al, 1999; Mathias et al, 1991; Piskareva 
et al, 2003; Piskareva & Schmatchenko, 2006), we reasoned that cellular RNase H2 may 
instead degrade the RNA in the L1 RNA:cDNA hybrid. To test if RNase H2 performs this 
function more generally for LINE elements lacking an RNase H domain, we next 
investigated the impact of RNase H2 deficiency on retrotransposition of a LINE-2 element 
from zebrafish (ZfL2-2). Notably, ZfL2-2 does not contain an RNase H domain and is active 
in human cells lines (Garcia-Perez et al, 2010; Sugano et al, 2006). We tagged this LINE-
2 element with an mneoI retrotransposition indicator cassette, which confers resistance to 
neomycin/G418 upon retrotransposition (Freeman et al, 1994; Moran et al, 1996) (Fig 3A), 
and measured activity in the HeLa RNASEH2A-KO and control clones. An active human 
LINE-1 tagged with the same retrotransposition indicator cassette (vector JM101/L1.3, Fig 
3A) was used in parallel as a control. The JM101/L1.3-mneoI vector produced results very 
similar to JJ101/L1.3-mblastI (Fig 1 and 3C). Consistent with our hypothesis, ZfL2-2-mneoI 
retrotransposition was significantly reduced in null clones (n = 5, 1.6±0.91%) compared to 
parental cells (set to 100%) and control clones (n = 5, 85±9.5%; P = 0.0079) (Fig 3A-C and 
EV2A). Notably, when ZfL2-2 was assayed in the U2OS RNASEH2A-KO and control 
clones, we observed a virtually identical outcome (Fig EV2B; n = 2 controls, 105±3.5% vs 
n = 2 KO, 14±2.4%; P = 0.0012). As expected, we detected a similar reduction in the 
retrotransposition rate of a human LINE-1 element in both HeLa and U2OS RNASEH2A-
KO clones using the mneoI-based assay (Fig 3A-C and EV2). Taken together, these data 
suggest that LINE elements lacking a functional RNase H domain rely on cellular RNase 
H2 activity to retrotranspose efficiently. This would make RNase H2 an integral part of the 
LINE retrotransposition machinery. 
In line with this model, we reasoned that retrotransposons that do contain a functional 
RNase H domain would not rely on cellular RNase H2 activity to retrotranspose efficiently. 
Active LTR-retrotransposons from the mouse genome contain a functional RNase H 
domain within their pol gene (Doolittle et al, 1989); they generate cytoplasmic RNA:cDNA 
hybrid intermediates during their retrotransposition cycle, with RNA degradation required 
to complete LTR-retrotransposition. We therefore measured retrotransposition of MusD, an 
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active LTR-retrotransposon from the mouse genome (Doolittle et al, 1989; Mager & 
Freeman, 2000). To do so, we tagged an active MusD element with the neoTNF 
retrotransposition indicator cassette (pCMVMusD-6 neoTNF; Fig 3D, Appendix Fig S2A; 
(Ribet et al, 2004)) and tested its activity in RNASEH2A-KO and control clones. Consistent 
with our model, the level of MusD retrotransposition was similar in HeLa control and 
RNASEH2A-KO clones (Fig 3D, Appendix Fig S2B). Similarly, no difference in MusD 
activity was observed either when comparing U2OS RNase H2 wildtype and null cells 
(Appendix Fig S2C). Thus, these data strongly suggest that retrotransposons containing a 
functional RNase H domain do not depend on cellular RNase H2 activity for their 
mobilization. 
We next tested whether mobilisation of DNA-Transposons, that move by a cut-and-paste 
mechanism that does not involve Reverse Transcription, would require cellular RNase H2 
activity. We employed an active Tc1-like resurrected DNA-Transposon termed Sleeping 
Beauty (SB) (Ivics et al, 1997) that transposes very efficiently in human cells. Using an SB 
transposition assay based on G418 selection, no differences in transposition rates were 
observed when comparing RNase H2 null clones and controls, for either HeLa (Fig 3E) or 
U2OS (Appendix Fig S2D) cell lines.  
We therefore conclude that neither LTR-retrotransposons that code for RNase H activity, 
nor DNA-Transposons, rely on cellular RNase H2 activity for their mobilisation.  
 
RNase H2 overexpression increases LINE-1 retrotransposition 
If RNase H2 is directly required for LINE-1 retrotransposition it may be expected that 
overexpression of RNase H2 might further increase retrotransposition efficiency, and we 
set out to test this. RNase H2 is a heterotrimeric enzyme, and overexpression of the 
catalytic subunit alone does not significantly increase cellular activity (KR Astell, MAM 
Reijns & AP Jackson, unpublished data). We therefore co-transfected HeLa and U2OS 
cells with three plasmids each expressing one of the RNase H2 subunits tagged with a V5 
epitope tag and an engineered human LINE-1 construct tagged with the mblastI indicator 
cassette (JJ101/L1.3). As controls, we transfected cells with a β-arrestin expression vector, 
a negative control (-ve) that does not significantly affect L1 retrotransposition (Bogerd et 
al, 2006), or with an APOBEC3A overexpression vector, a positive control (+ve) that 
strongly inhibits LINE-1 retrotransposition (Bogerd et al, 2006; Richardson et al, 2014). 
Cells were also co-transfected in a parallel assay with the control vector pcDNA6.1, and 
resulting colony numbers used for normalisation to control for potential toxic side effects of 
cDNA overexpression. Notably, when HeLa or U2OS cells were co-transfected with equal 
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amounts of overexpression plasmid for each RNase H2 subunit (ratio 1:1:1) and vector 
JJ101/L1.3, we detected a significant increase in retrotransposition when compared to the 
β-arrestin control (2.1-fold in HeLa and 1.7-fold in U2OS, Fig 4). In agreement with previous 
reports (Bogerd et al, 2006), overexpression of APOBEC3A reduced LINE-1 
retrotransposition to ~10% of control levels (Fig 4, (Bogerd et al, 2006)). As expected, RT 
mutant LINE-1s failed to retrotranspose in any condition tested and the retrotransposition 
of EN mutant LINE-1s was not affected by RNase H2 overexpression (Fig 4), suggesting 
that RNase H2 cleavage at misincorporated ribonucleotides does not provide an entry point 
for endonuclease mutant LINE-1s. Western blot analysis showed that the three V5-tagged 
RNase H2 subunits were expressed, although they were not detected at the same level 
(Fig EV3A). Through optimisation, we found that a 14:7:1 transfection ratio (for 
RNASEH2A, B and C respectively) produced the most similar expression levels for each 
of the subunits (Fig EV3A). When measuring retrotransposition at this 14:7:1 ratio, LINE-1 
retrotransposition increased again, this time by ~1.7-fold for HeLa cells and ~1.4-fold for 
U2OS cells (Fig EV3B, C). Thus, rather than reduced LINE-1 retrotransposition being an 
indirect effect of RNase H2 deficiency, these data are consistent with a direct role for 
cellular RNase H2 in facilitating LINE-1 retrotransposition. 
 
Complementation of KO cells with wildtype, but not separation of function 
RNASEH2A rescues LINE-1 retrotransposition 
RNase H2 can cleave at ribonucleotides embedded in double stranded DNA, and can 
hydrolyse the RNA strand of RNA:DNA heteroduplexes, raising the question as to which of 
these two activities is required to promote LINE-1 retrotransposition. Elegant work in yeast 
identified two amino acid changes in the RNase H2 catalytic subunit that severely 
abrogates its activity against single embedded ribonucleotides, while retaining activity 
against RNA:DNA heteroduplexes (Chon et al, 2013). We took advantage of this 
“separation of function” (SoF) mutant to try to address this question (Fig EV4A). First, we 
tested whether the biochemical characteristics of recombinant human RNase H2 with the 
equivalent mutations (P40D/Y210A) were similar to that of the yeast enzyme (Fig 5A-D, 
and (Chon et al, 2013)). As expected, recombinant human SoF RNase H2 has virtually no 
activity against single embedded ribonucleotides (Fig 5A, B), but retains activity against 
RNA:DNA heteroduplexes (Fig 5C, D). However, activity against RNA:DNA heteroduplex 
substrate was reduced compared to wildtype RNase H2, and unexpectedly, we also found 
that the SoF mutant produced longer RNA products when compared to wildtype RNase H2 
(Fig 5C), suggestive of an altered cleavage pattern. This difference in cleavage was 
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observed even with higher enzyme concentrations and at longer incubation times (Fig 
EV4B).  
We next complemented a HeLa RNASEH2A-KO clone (KO1) using retroviral vectors to 
generate stable cell lines expressing either wildtype or SoF RNASEH2A. Cell lines 
expressing the empty vector (EV) or catalytically inactive (Catalytic dead, CD) RNASEH2A 
(D34A/D169A; (Reijns et al, 2011)) were also generated and used as controls. Western 
blotting confirmed expression of RNASEH2A and the consequent stabilisation of 
RNASEH2B and C in complemented cells at levels indistinguishable from control cells (Fig 
5E). As expected, complementation with WT RNASEH2A but not EV, SoF or CD reduced 
the level of ribonucleotide incorporation to a level similar to that observed in wildtype 
controls (Fig EV4C). This was consistent with the level of RNase H activity against single 
embedded ribonucleotides measured in cell lysates in complemented cells (Fig 5F and 
EV4D, E). On the other hand, activity against RNA:DNA heteroduplexes was similar for the 
WT complemented cells (+WT) and wildtype control cells (C1), whereas the SoF 
complemented cells displayed <50% activity (Fig 5G and EV4F,G), in line with the observed 
reduction in activity of recombinant SoF RNase H2. RNase H1 is expressed in all of these 
cells, explaining the residual activity against RNA:DNA substrate in RNASEH2A-KO cells 
complemented with empty vector or RNASEH2A-CD. Notably, the altered cleavage pattern 
on RNA:DNA hybrids was also detected in cell lysates from RNASEH2A-SoF 
complemented cells (Fig EV4G). These data suggest that, although the P40D/Y210A 
amino acid changes in human RNase H2 do act as separation of function mutations, RNase 
H activity against RNA:DNA heteroduplexes of the SoF mutant is compromised both in vitro 
and in vivo. 
Retrotransposition assays on the complemented cell lines using vector JJ101/L1.3 
demonstrated that complementation with wildtype RNASEH2A allowed efficient 
retrotransposition (Fig 5H). A second HeLa RNASEH2A-KO clone (KO2) complemented 
with WT RNASEH2A also showed rescue of the L1-retrotransposition defect (Fig EV4H), 
confirming that reduced retrotransposition in RNASEH2A-KO cells is due to lack of RNase 
H2 activity and not due to potential off-target effects of CRISPR/Cas9. In contrast, 
complementation with RNASEH2A-SoF failed to rescue the L1 retrotransposition defect, 
with levels similar to those seen in EV or CD complemented cells (Fig 5H). Failure to 
complement the LINE-1 retrotransposition defect in RNase H2 null cells with the 
RNASEH2A separation of function mutant may be a direct consequence of its altered 
biochemical characteristics, resulting in its failure to fully/efficiently degrade the RNA in the 
LINE-1 RNA:cDNA hybrid. However, it is formally possible that RNase H2 promotes LINE-
1 retrotransposition through its activity on embedded ribonucleotides. 
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No increased mutation rates in newly inserted LINE-1 elements in RNase H2 null 
cells 
It has been shown that during Human Immunodeficiency virus type 1 (HIV-1) reverse 
transcription, ribonucleotides are misincorporated at high frequency by the RT of HIV-1, 
especially in macrophages (Kennedy et al, 2012). Notably, RNase H2 was shown in a high 
throughput screen to be important for HIV-1 infection (Genovesio et al, 2011), and it may 
be involved in removing such embedded ribonucleotides. Although drastic differences exist 
among the mechanism of retroviral insertion and LINE-1 retrotransposition, it is therefore 
possible that ribonucleotides are misincorporated during L1 reverse transcription and/or 
second strand synthesis, and that their removal by RNase H2-dependent RER is important 
to allow efficient retrotransposition to occur. Ribonucleotide misincorporation in RNase H2 
deficient yeast was shown to cause high rates of Top1-dependent 2-5 bp deletions (Kim et 
al, 2011; Nick McElhinny et al, 2010). These mutations are most likely to occur at tandem 
dinucleotide repeats, particularly CA:TG and GA:TC (Clark et al, 2011; Kim et al, 2013; Kim 
et al, 2011; Potenski et al, 2014). These repeats occur in our retrotransposition reporters 
at rates similar to the yeast reporters, and as such mutations are likely to inactivate the 
drug selectable marker used in our assays, this could explain the apparent reduction in 
retrotransposition in RNase H2 null cells. We therefore set out to determine the occurrence 
of such mutations in newly inserted LINE-1 elements in RNase H2 null and control cells. 
To do this, we transfected plasmid JM101/L1.3, containing the mneoI retrotransposition 
cassette, into RNase H2 null HeLa clones (KO1 and KO2) and parental cells, and allowed 
cells to grow for 5 days without G418 selection (Appendix Fig S3A, B). Two and five days 
after transfection, genomic DNA was isolated and analysed by conventional PCR, using 
intron-spanning primers and thus allowing us to distinguish retrotransposed products 
(shorter amplification products) from the transfected vector (Appendix Fig S3A, C). 
Sequencing of amplification products corresponding to the spliced mneoI reporter (i.e. de 
novo L1 insertions) showed no increase in mutations in RNASEH2A-KO cells compared to 
RNase H2 proficient cells (Appendix Fig S3D, E). Notably, only missense mutations were 
identified, with no 2-5 bp deletions detected in any of the clones analysed. We therefore 
conclude that the LINE-1 retrotransposition defect in RNase H2 null cells is not caused by 
hypermutation of de novo L1 insertions that could result from failure to remove 
ribonucleotides misincorporated during TPRT.  
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SoF RNase H2 overexpression supports increased LINE-1 retrotransposition, 
despite reduced substrate affinity  
We reasoned that overexpression of the RNase H2 SoF mutant may compensate for its 
reduced activity against RNA:DNA hybrids, and tested the effect of simultaneous 
overexpression of RNASEH2A-P40D/Y210A, RNASEH2B and RNASEH2C on LINE-1 
retrotransposition. We found that overexpression of SoF RNase H2 indeed leads to 
increased LINE-1 retrotransposition compared to the β-arrestin control (Fig 6A, P = 0.019). 
To further investigate why the separation of function mutant failed to rescue 
retrotransposition in the complemented RNASEH2A-KO cells, whereas its overexpression 
did support a higher rate of retrotransposition, we compared enzyme kinetics for SoF and 
wildtype RNase H2 on RNA:DNA substrate (Fig EV4I). We established that the SoF mutant 
has much reduced substrate affinity (KmSoF ~ 16x KmWT), whereas its maximum substrate 
conversion rate is similar to that of WT RNase H2 (kcatSoF ~ 0.83x kcatWT). The reduced 
substrate affinity of SoF RNase H2 therefore provides a likely explanation for our 
observations. These findings are in keeping with a role for the activity of RNase H2 against 
RNA:DNA hybrids to support LINE-1 retrotransposition. 
 
RNase H1 overexpression partially rescues LINE-1 retrotransposition in RNase H2 
null cells  
We assume RNase H1 to be expressed at normal levels in RNASEH2A-KO cells, and 
because of the marked reduction in LINE-1 retrotransposition in such null cells, it is unlikely 
that RNase H1 plays a major role in L1 retrotransposition. However, its activity against 
RNA:DNA hybrids may still contribute and could explain the variable level of remaining 
retrotransposition observed in our different RNase H2 null cells; retrotransposition was 
reduced between 4- and 15-fold compared to parental cells, depending on the cell line 
used. We therefore tested the effect of complementing HeLa RNASEH2A-KO cells with 
RNase H1. Two independent HeLa RNASEH2A-KO clones (KO1 and KO2) were 
transduced with a retroviral vector expressing the nuclear isoform of human RNase H1. To 
confirm overexpression of RNase H1, activity against RNA:DNA heteroduplexes was 
measured in lysates of these cells, showing a small but significant increase in enzyme 
activity (Fig 6B and Appendix Fig S4); RNASEH2A-KO1 cells complemented with wildtype 
RNase H1 displayed a 1.6-fold increase, while RNASEH2A-KO2 displayed a 2.2-fold 
increase in cleavage of RNA:DNA heteroduplexes, when compared to the corresponding 
EV complemented cells. As expected, no effect on RNase H activity against single 
embedded ribonucleotides was observed in the RNase H1 complemented cells (Fig 6C). 
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Next, we performed L1 retrotransposition assays using vector JJ101/L1.3, with 
RNASEH2A-complemented cells as positive controls. Notably, RNase H1 
complementation partially alleviated the L1 retrotransposition defect seen in the parental 
RNASEH2A-KO clones, but not to the same extent as RNASEH2A complementation (3.4-
fold increase for RNASEH2A vs 2.2-fold increase for RNase H1 compared to parental KO1; 
2.5-fold vs 1.8-fold increase respectively for KO2, Fig 6D, E). Controls revealed that similar 
numbers of blasticidin-resistant colonies were formed for all cell lines when transfected with 
the control plasmid pcDNA6.1 (Fig 6D). Due to the relatively low increase in cellular RNase 
H activity against RNA:DNA heteroduplexes, failure to fully rescue retrotransposition is 
perhaps not surprising. However, the ability of RNase H1 to partially rescue L1 activity is 
consistent with the possibility that both cellular RNase H enzymes could facilitate L1 
retrotransposition, and would be in line with a model in which these nucleases degrade the 
RNA:cDNA hybrid formed during TPRT. We therefore propose that RNase H2 facilitates 
LINE-1 retrotransposition by removing LINE-1 RNA after reverse transcription, allowing 
completion of the LINE-1 insertion event, with a minor contribution from nuclear RNase H1 
(Fig 6F). 
 
Reduced LINE-1 retrotransposition due to RNase H2 disease mutations 
Overall, our data suggest that LINE-1 retrotransposition is likely to be reduced in cells from 
AGS patients with RNase H2 mutations, as most of these are known to cause reduced 
cellular enzyme activity. We confirmed the impact of disease mutations in any of the three 
subunits using recombinant RNase H2, but did not find the same change in cleavage 
pattern observed for the separation of function mutant (Fig EV5A, B). We speculate that 
the altered cleavage pattern for the latter may be due to its reduced substrate affinity, an 
effect that may be more pronounced closer to the substrate 3’ end. To determine the 
cellular effect of RNase H2 disease mutations, we complemented RNASEH2A-KO cells 
with RNASEH2A-G37S and RNASEH2A-E225G, the only two missense mutations that 
have been found so far as causative homozygous changes in the catalytic subunit in AGS 
patients (Rice et al, 2013). Western-blot analyses revealed that these cells express mutant 
RNASEH2A (Fig 7A), leading to a small, but significant increase in cellular RNase H2 
activity (Fig 7B). Notably, we observed partial rescue of LINE-1 retrotransposition in cells 
complemented with RNASEH2A-G37S and RNASEH2A-E225G (Fig 7C, D). Importantly, 
both AGS mutants displayed significantly reduced retrotransposition compared to 
RNASEH2A-WT complemented cells (n = 3, P = 0.003 for G37S, and P = 0.018 for E225G). 
Therefore, based on our data, we would expect AGS patients with RNase H2 mutations to 
have reduced levels of productive LINE-1 retrotransposition. 
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Discussion 
RNase H2 has been suggested to control LINE-1 retrotransposition (Volkman & Stetson, 
2014), similar to other AGS genes. While our work was under revision, Choi et al published 
work that suggests that RNase H2 may indeed act as a LINE-1 restriction factor (Choi et 
al, 2018). However, contrary to these findings, our results, using multiple independent 
CRISPR/Cas9 edited RNase H2 null clones, three different cell lines and several 
engineered LINE retrotransposition reporters, provide comprehensive evidence to support 
a role for cellular RNase H2 activity in promoting LINE-1 retrotransposition. Furthermore, 
our findings are consistent with a recent report that also found RNase H2 to be required for 
retrotransposition (Bartsch et al, 2017). We also demonstrate that other retrotransposons 
lacking an RNase H domain also rely on cellular RNase H activity to mobilise. In contrast, 
retrotransposons that code for an RNase H domain/activity did not require cellular RNase 
H2 to retrotranspose efficiently. Complementation of the retrotransposition defect in RNase 
H2 null cells by RNase H1 overexpression, and increased retrotransposition upon 
overexpression of the RNase H2 separation of function mutant lead us to propose a model 
in which RNase H2 degrades LINE-1 RNA in the RNA:cDNA retrotransposition 
intermediate generated during TPRT (Fig 6F). 
Recently, a PCNA-Interaction-Protein (PIP) motif was identified in L1-ORF2p (Taylor et al, 
2013), and the interaction between L1-ORF2p and PCNA was shown to be required for 
efficient retrotransposition. As RNASEH2B also contains a functional PIP domain that 
allows RNase H2 to interact with PCNA (Bubeck et al, 2011; Chon et al, 2009) we speculate 
that PCNA might act as an anchor protein connecting L1-ORF2p with RNase H2 during 
retrotransposition. This may also explain why RNase H1, which lacks a PIP domain, cannot 
efficiently complement the L1-retrotransposition defect inherent to RNase H2 null cells. 
However, nuclear RNase H1 could process LINE-1 RNA:cDNA hybrids by a simple but less 
efficient diffusion mechanism. Whether the interaction between PCNA and RNase H2 
indeed contributes to efficient retrotransposition remains to be determined.  
Our model, in which cellular RNase H activity promotes completion of LINE-1 
retrotransposition by degrading the RNA from RNA:cDNA hybrids generated during TPRT 
(Fig 6F), would explain how LINE-1 elements can function without an active RNase H 
domain (Malik et al, 1999; Olivares et al, 2002). We provided several lines of evidence 
supporting this model: i) strongly reduced LINE-1 retrotransposition in RNase H2 null cells; 
ii) rescue of this defect by wildtype RNASEH2A as well as iii) RNase H1 overexpression; 
and iv) increased retrotransposition upon overexpression of both wildtype and separation 
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of function RNase H2. Our work shows that RNase H activity directed against RNA:DNA 
hybrids, mainly provided by cellular RNase H2, is important for efficient and productive 
LINE-1 retrotransposition. We interpret this to mean that it is involved in degrading LINE-1 
RNA in the RNA:cDNA hybrid, allowing second strand synthesis and ultimately insertion 
into the genome. Alternative explanations are of course possible. As there is increasing 
evidence that DNA double strand break repair can be mediated by RNA (Keskin et al, 2014; 
Michelini et al, 2017; Ohle et al, 2016), one intriguing possibility is that RNA:DNA hybrids 
play a more active role in the LINE-1 retrotransposition process, for example by recruiting 
RNase H2 and DNA repair machinery. Furthermore, RNase H2 deficiency can also cause 
larger genomic rearrangements (Reijns et al, 2012) which might impact on LINE-1 
retrotransposition. Although we cannot rule out that this type of genome instability interferes 
with retrotransposition, or even that non-productive retrotransposition contributes to 
increased genomic rearrangements in RNase H2 null cells, it seems unlikely that this is the 
reason for the reduced LINE-1 retrotransposition we observe, particularly as RNase H2 
overexpression leads to increased rates of retrotransposition.   
As mutations in the genes encoding RNase H2 are a frequent cause of AGS, our findings 
are relevant with regards to possible sources of immunostimulatory nucleic acids thought 
to cause autoinflammation. Two sources for such cytoplasmic nucleic acids have been 
proposed: DNA damage or retroelements. Notably, active LINE-1s are expressed and 
highly active in the central nervous system (Coufal et al, 2009; Muotri et al, 2005) and 
strong experimental evidence suggest that TREX1, SAMHD1 and ADAR1 act as LINE-1 
restriction factors (Orecchini et al, 2017; Stetson et al, 2008; Thomas et al, 2017; Zhao et 
al, 2013). Although one study failed to detect elevated retrotransposition of L1s in the 
hippocampus of an AGS patient with SAMHD1 mutations (Upton et al, 2015), more recent 
work using TREX1-deficient neural cells generated from human embryonic stem cells has 
strongly implicated accumulating LINE-1 derived single-stranded DNAs (ssDNAs) in type I 
IFN production and neurotoxicity (Thomas et al, 2017), consistent with a role for active 
LINE-1s in AGS pathophysiology (Garcia Perez & Alarcon-Riquelme, 2017). This work also 
reinforces the concept that byproducts of active retrotransposition, rather than the 
accumulation of LINE-1 insertions per se, may be the driver of AGS pathology (Upton et 
al, 2015), with TREX1 normally degrading LINE-1 ssDNA retrotransposition intermediates 
(Garcia Perez & Alarcon-Riquelme, 2017; Stetson et al, 2008; Thomas et al, 2017).  
Very recently, we have demonstrated both increased DNA damage and cGAS-STING 
dependent upregulation of interferon-stimulated genes (ISG) in RNase H2 null MEFs 
(Mackenzie et al, 2016). Furthermore, we established a mechanism linking genome 
instability to inflammation, with micronuclei providing a source of cytoplasmic DNA able to 
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activate cGAS, (Mackenzie et al, 2017), although the direct relevance of this to AGS 
remains to be determined. Notably, neither DNA damage nor the ISG response was 
alleviated by overexpression of RNase H1 (Mackenzie et al, 2016), in contrast to partial 
rescue of the retrotransposition defect in RNase H2 null HeLa cells overexpressing RNase 
H1 (Fig 6). We therefore favour the possibility that genome stability is the underlying cause 
of autoinflammation in AGS associated with RNase H2 mutations. However, because 
RNase H2 activity is required for LINE-1 retrotransposition and we show that cells with 
RNase H2 disease mutations have reduced levels of productive retrotransposition, it is 
formally possible that accumulation of nuclear LINE-1 RNA:cDNA hybrids is a source of 
immunostimulatory nucleic acids. How such hybrids that are covalently linked to the 
genome would access the cytoplasm and activate pattern recognition receptors is currently 
unclear though. An additional remaining question is whether physiological levels of 
retrotransposition byproducts are sufficient to elicit the observed inflammatory response. 
Clearly, further work is therefore needed to determine the relative importance of 
retroelement activity and genome instability in AGS. This will not be straight forward, as 
the two are not necessarily mutually exclusive.  
In summary, our work contributes to the mechanistic understanding of LINE-1 
retrotransposition, as we demonstrate that cellular RNase H2 plays an integral part in LINE 
retrotransposition, explaining how LINE elements lacking an RNase H domain can 
retrotranspose. In addition, our data adds a new layer of complexity to the understanding 
of AGS pathophysiology, as we demonstrate that not all AGS proteins are LINE restriction 
factors. 
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Material and Methods 
Cell culture  
HeLa cells, a kind gift from G. Stewart (Birmingham) originally obtained from ATCC, were 
grown in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Cat no 41965-039) 
supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin and 50 μg/ml 
streptomycin. U2OS cells purchased from the European Collection of Authenticated Cell 
Cultures (ECACC, Cat no. 92022711) and HCT116 p53-/- cells (Bunz et al, 1998; Dornan 
et al, 2004), a kind gift from K. Ball (Edinburgh), were maintained in modified McCoy’s 5A 
medium (Gibco; Cat no 26600-023) supplemented with 10% FBS, 50 U/ml penicillin and 
50 μg/ml streptomycin.  
All cell lines were grown at 37˚C, 5% CO2 and atmospheric O2, and passaged using Trypsin 
(Gibco). Checks were performed at least once a month using the Lonza-Mycoalert 
Mycoplasma Detection Kit to ensure that all cells were mycoplasma-free. In addition, the 
identity of the cell lines was confirmed by SRT analyses at least once a year (Lorgen, 
Granada, Spain). 
 
Plasmid DNA 
All plasmids were purified using a Plasmid Midi kit from Qiagen. DNA was analysed by 
electrophoresis (0.7% agarose-ethidium bromide gels) and only highly supercoiled DNA 
preparations were used in transfection experiments. Cloning strategies are available upon 
request. 
pSpCas9n(RNASEH2A-g1)-2A-GFP and pSpCas9n(RNASEH2A-g2)-2A-Puro express 
guide RNAs (gRNAs) designed against exon 1 (TGCCCGCCTCATCGACGCCC) and 
intron 1 (CCCGTGCTGGGTGCGCCCCT) of human RNASEH2A, and Cas9n (D10A 
nickase mutant) fused to the cDNA of Enhanced Green Fluorescent Protein (EGFP) and 
puromycin N-acetyl-transferase (puro) respectively. gRNAs were generated by annealing 
DNA oligonucleotides and were cloned into the BbsI site of pSpCas9n(BB)-2A-GFP and 
pSpCas9n(BB)-2A-Puro vectors (Addgene plasmids #48140 and #48141, respectively; 
gifts from Feng Zhang) as previously described (Ran et al, 2013). 
pMSCVpuro-RNASEH2A-WT, coding sequence of human RNASEH2A (NM_006397.2) 
cloned into vector pMSCVpuro-Dest, a Gateway compatible version of pMSCVpuro 
(Clontech). 
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pMSCVpuro-RNASEH2A-SoF, a derivative of plasmid pMSCVpuro-RNASEH2A-WT  that 
contains two missense mutations in the coding sequence of human RNASEH2A 
(P40D/Y210A, separation of function mutant (Chon et al, 2013)). 
pMSCVpuro-RNASEH2A-CD, a derivative of plasmid pMSCVpuro-RNASEH2A-WT  that 
contains two missense mutations in the coding sequence of human RNASEH2A 
(D34A/D169A, catalytically inactive (Reijns et al, 2011)). 
pMSCVpuro-RNaseH1, coding sequence of the nuclear isoform of the human RNASEH1 
gene (NM_002936.5, aa27-286) cloned into pMSCVpuro-Dest. 
pcDNA3.1/nV5-RNASEH2A, coding sequence of human RNASEH2A cloned into vector 
pcDNA3.1/nV5-DEST (contains an N-terminal V5 tag). 
pcDNA3.1/nV5-RNASEH2A-SoF, coding sequence of human RNASEH2A with 
P40D/Y210A missense mutations cloned in vector pcDNA3.1/nV5-DEST (contains an N-
terminal V5 tag). 
pcDNA3.1/nV5-RNASEH2B, coding sequence of human RNASEH2B (NM_024570.3) 
cloned into pcDNA3.1/nV5-DEST (contains an N-terminal V5 tag). 
pcDNA3.1/nV5-RNASEH2C, contains the coding sequence of the human RNASEH2C 
gene (NM_032193.3) cloned in pcDNA3.1/nV5-DEST (contains an N-terminal V5 tag). 
pK-βarr, described previously (Bogerd et al, 2006) and expresses C-terminally HA-tagged 
human β-Arrestin. 
pK-A3A, described previously (Bogerd et al, 2006) and expresses C-terminally HA-tagged 
human APOBEC3A. 
pU6ineo, described previously (Richardson et al, 2014). Contains the neomycin 
phosphotransferase (NEO) expression cassette from pEGFP-N1 (Clontech) cloned into a 
modified pBSKS-II(+) (Stratagene) that contains a U6 promoter in the multi-cloning site. 
pcDNA6.1, (Invitrogen) contains an expression cassette for blasticidin-S deaminase. 
JM101/L1.3, described previously (Sassaman et al, 1997) and contains a full-length copy 
of the human L1.3 element tagged with the mneoI indicator cassette (Freeman et al, 1994; 
Moran et al, 1996) and is cloned in pCEP4 (Life Technologies). 
JM101/L1.3-D205A, described previously (Wei et al, 2001); a derivative of JM101/L1.3 that 
contains a missense mutation in the EN domain of L1-ORF2p (D205A). 
JM101/L1.3-D702A, was described previously (Wei et al, 2001); a derivative of JM101/L1.3 
that contains a missense mutation in the RT domain of L1-ORF2p (D702A). 
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JJ101/L1.3, described previously (Kopera et al, 2011). It contains a full-length copy of the 
human L1.3 element (Sassaman et al, 1997) tagged with the mblastI indicator cassette 
(Goodier et al, 2007; Morrish et al, 2002) and is cloned in pCEP4 (Life Technologies). 
JJ101/L1.3-D205A, described previously (Kopera et al, 2011); a derivative of JJ101/L1.3 
that contains a missense mutation in the EN domain of L1-ORF2p (D205A). 
JJ101/L1.3-D702A, described previously (Kopera et al, 2011); a derivative of JJ101/L1.3 
that contains a missense mutation in the RT domain of L1-ORF2p (D702A). 
pXY014, described previously (Xie et al, 2011); contains a full-length copy of the human 
L1RP element (Kimberland et al, 1999) tagged with the mflucI indicator cassette (Xie et al, 
2011) and is cloned in a modified pCEP4 (Life Technologies) that contains a Renilla firefly 
expression cassette. 
pXY017, described previously (Xie et al, 2011); a derivative of pXY014 that contains two 
missense mutations in the RNA binding domain of L1-ORF1p (RR261/62AA). This plasmid 
was used as a negative control of the luciferase-based retrotransposition assays. 
pCMVMusD-6neoTNF, described previously (Ribet et al, 2004); contains a full-length copy 
of a mouse MusD element (AC124426, positions 9078–16,569 (+)) tagged with the neoTNF 
indicator cassette (Esnault et al, 2002) and is cloned in vector pCMVbeta (Clontech). 
Zfl2-2mneoI, described previously (Garcia-Perez et al, 2010; Sugano et al, 2006); contains 
a full-length copy of the zebrafish Zfl2-2 element tagged with the mneoI indicator cassette 
inside the 3´UTR of the LINE (Freeman et al, 1994; Sugano et al, 2006) and is cloned in 
pCEP4 (Life Technologies). 
pT2neo, described previously (Mates et al, 2009); contains an SV40-driven neomycin 
phosphotransferase cDNA flanked by SB TIRs. 
pCMV-SB100x, described previously (Mates et al, 2009); contains a CMV-driven 
hyperactive SB Transposase.  
pCEP-EGFP, described previously (Alisch et al, 2006); contains the coding sequence of 
the humanized EGFP protein cloned in pCEP4 (Invitrogen). 
pGEX6P1-hsRNASEH2BCA, pGEX6P1-hsRNASEH2BCA(D34A/D169A), pGEX6P1-
hsRNASEH2B(A177T)CA and pGEX6P1-hsRNASEH2BC(R69W)A,  described 
previously (Reijns et al, 2011) allow expression in E. coli of GST-tagged human 
RNASEH2B and non-tagged RNASEH2C and A subunits. Amino acid substitutions 
indicated in brackets were introduced into the relevant subunits by site-directed 
mutagenesis. 
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pGEX6P1-hsRNASEH2BCA(P40D/Y210A), pGEX6P1-hsRNASEH2BCA(G37S) and 
pGEX6P1-hsRNASEH2BCA(E225G) had the P40D/Y210A separation of function 
mutations, and G37S and E225G AGS mutations respectively introduced into RNASEH2A 
by site-directed mutagenesis. 
 
Generation of RNASEH2A knockout cell lines 
To establish RNASEH2A-KO cell lines, cells were seeded in 6-well plates and transfected 
with the two vectors encoding both the sgRNAs and Cas9n using Lipofectamine 2000 
(Thermo Fisher Scientific). Forty-eight hours after transfection, single EGFP-expressing 
cells were sorted into 96-well plates on a BD FACSJazz instrument (BD Biosciences) and 
grown until cell lines formed. RNASEH2A-KO clones were selected on the basis of the size 
of PCR products of the targeted region, and deletions/insertions subsequently confirmed 
by Sanger DNA sequencing. Oligonucleotides (5’ to 3’) used for PCR amplification and 
sequencing of targeted RNASEH2A loci were 5´-ACCCGCTCCTGCAGTATTAG and 5´-
TCCCTTGGTGCAGTGCAATC. The absence of functional RNASEH2A was confirmed by 
immunoblotting, by an RNase H2 activity assay, and using  alkaline gel electrophoresis as 
described below. Only clones confirmed to be functionally null were used for subsequent 
experiments. Some knockout clones retained very low levels of RNASEH2A protein 
expression, apparent upon long exposure of immunoblots. For these clones, Sanger 
sequencing showed the presence of in-frame deletions, in each case removing essential 
catalytic site residues, including Asp34, rendering them enzymatically non-functional. 
Clones expressing wild-type RNASEH2A protein were identified in parallel and used as 
controls.  
 
Retroviral complementation 
To complement RNASEH2A-KO HeLa clones, cells were infected with retroviral 
supernatant produced in Amphotropic Phoenix packaging cells (Swift et al, 2001) using 
pMSCVpuro-based vectors, in the presence of 4 μg/ml polybrene and selected for stable 
integration using 2 μg/ml puromycin.  
 
Whole Cell extracts preparation and western blot analysis 
Whole cell extracts (WCE) for RNase H activity assays and for determining protein levels 
of RNase H2 subunits were prepared by incubating cells in lysis buffer (50 mM Tris-HCl pH 
8.0, 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 0.2 mM EGTA, 10% glycerol (vol/vol), 1 
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mM DTT and 1 mM phenylmethyl-sulfonyl fluoride (PMSF)) for 10 min on ice, followed by 
the addition of an equal volume of 20 mM HEPES pH 7.9, 10 mM KCl, 1 mM EDTA, 10% 
glycerol (vol/vol), 1 mM DTT and 1 mM PMSF for an additional 10 min. Whole cell extracts 
were cleared by centrifugation (17,000 g for 10 min at 4°C) and protein concentration was 
determined by Bradford assay (Protein Assay Kit, BioRad).  
In overexpression assays conducted with HeLa and U2OS cells, WCEs were prepared 
using RIPA buffer (Sigma) supplemented with 1x Complete Mini EDTA-free Protease 
Inhibitor cocktail (Roche), 0.1% Phosphatase Inhibitor 1&2 (Sigma), 1mM (PMSF) (Sigma) 
and 0.25% β-mercaptoethanol (Sigma), incubating cells for 10 min on ice. Cellular debris 
was removed by centrifugation (1,000 g for 5 min at 4°C) and total protein concentration 
was determined using the Micro BCA Protein Assay Kit (Thermo) following standard 
procedures. 
Equal amounts of protein lysates were run on SDS-PAGE gels and transferred to PVDF or 
nitrocellulose membranes (Bio-Rad). Membranes were blocked in 5% milk / TBST (TBS + 
0.2% Tween-20 (v/v)) and incubated with primary antibodies diluted in 5% milk/TBST 
overnight at 4˚C. Membranes were then washed 3 times with TBST, incubated with 
secondary antibodies for 1 h at RT, washed again and developed. As secondary 
antibodies, we used Horseradish Peroxidase (HRP)-linked Antibodies (Cell Signaling) and 
either Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life 
Sciences) or an Inmun-StarTM Western CTM Detection Kit (BIO-RAD). The light signal 
was captured on X-ray films or using an ImageQuantLAS4000 device following 
manufacturer’s recommendations. To quantify L1-ORF1p expression levels, we used an 
infrared fluorescent detection system (Odyssey, LI-COR) following manufacturer’s 
recommendations. 
The following antibodies were used for immunoblotting (at indicated dilutions): sheep anti-
RNase H2 (raised against human recombinant RNase H2 (Reijns et al, 2012), 1:1,000); 
rabbit anti-RNASEH2A (Origene TA306706, 1:1,000) or mouse anti-RNASEH2A (Santa 
Cruz sc-515475, 1:1,000); mouse anti-α-tubulin B512 (Sigma T6074, 1:5,000); mouse anti-
vinculin (Sigma V9264, 1:1,000); rabbit anti-L1Hs-ORF1p (provided by Dr Oliver 
Weichenrieder, Max-Planck, Germany, (Macia et al, 2017) 1:5,000); mouse anti–β-actin 
(1:20,000; Sigma); mouse anti-V5 (clone V5-10, Sigma V8012, 1:10,000). In quantitative 
westerns, goat anti-rabbit and anti-mouse fluorescent secondary antibodies were used at 
a 1:20,000 dilution.  
 
RNase H2 activity assay  
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To assess RNase H2 activity in whole cell extracts, a FRET-based fluorescent substrate 
release assay was performed as previously described (Reijns et al, 2011). Briefly, RNase 
H2-specific activity was determined by measuring cleavage of a single embedded 
ribonucleotide containing double stranded DNA substrate (DRD:DNA). Activity against a 
DNA:DNA substrate of the same sequence was used to correct for non-RNase H2 
“background activity” against the DRD:DNA substrate. Substrates were formed by 
annealing a 3’-fluorescein-labelled oligonucleotide (5´GATCTGAGCCTGGGaGCT or 
5´GATCTGAGCCTGGGAGCT; uppercase DNA, lowercase RNA) to a complementary 5’ 
DABCYL-labelled DNA oligonucleotide (Eurogentec).  Reactions were performed in 100 µl 
of reaction buffer (60 mM KCl, 50 mM Tris-HCl pH 8.0, 10 mM MgCl2, 0.01% BSA, 0.01% 
Triton X-100) with 250 nM substrate in 96-well flat-bottomed plates at 24°C. Whole cell 
lysates were prepared as described above, and the final protein concentration used per 
reaction was 100 ng/µl. Fluorescence was read (100 ms) every 5 min for up to 90 min using 
a VICTOR2 1420 multilabel counter (Perkin Elmer), with a 480-nm excitation filter and a 
535-nm emission filter. 
To assess RNase H2 activity in whole cell extracts using the gel-based assay, a range of 
protein concentrations (50 – 400 ng/μl) was incubated with 2 μM substrate (described 
above; 5´gatctgagcctgggagct for RNA:DNA) in 5 μl reactions at 37°C for 30 min or 1 h. 
Reactions were stopped through addition of an equal volume of 96% formamide, 20 mM 
EDTA, and heating at 95°C. Products were resolved by denaturing PAGE (20%, 1x TBE), 
visualized on a FLA-5100 imaging system (Fujifilm) and quantified using ImageQuant TL 
(GE Healthcare). 
 
Detection of Ribonucleotides in Genomic DNA 
Total nucleic acids were isolated from ~1 million cells by lysis in ice-cold buffer (20 mM 
Tris-HCl pH 7.5, 75 mM NaCl, 50 mM EDTA) and subsequent incubation with 200 µg/ml 
proteinase K (Roche) for 10 min on ice followed by addition of N-Lauroylsarcosine sodium 
salt (Sigma) to a final concentration of 1%. Nucleic acids were sequentially extracted with 
TE-equilibrated phenol, phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform, then 
precipitated with isopropanol, washed with 75% ethanol and dissolved in nuclease-free 
water.  
For alkaline gel electrophoresis, 500 ng of total nucleic acids were incubated with 1 pmol 
of purified recombinant human RNase H2 (Reijns et al, 2011) and 0.25 μg of DNase-free 
RNase (Roche) for 30 min at 37°C in 100 µl reaction buffer (60 mM KCl, 50 mM Tris-HCl 
pH 8.0, 10 mM MgCl2, 0.01% BSA, 0.01% Triton X-100). Nucleic acids were ethanol 
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precipitated, dissolved in nuclease-free water and separated on 0.7% agarose in 50 mM 
NaOH, 1 mM EDTA. After electrophoresis, the gel was neutralised in 0.7 M Tris-HCl pH 
8.0, 1.5 M NaCl and stained with SYBR Gold (Invitrogen). Imaging was performed on a 
FLA-5100 imaging system (Fujifilm), and densitometry plots generated using an AIDA 
Image Analyzer (Raytest).  
 
Retrotransposition Assays  
LINE-1 retrotransposition assays in RNASEH2A-KO and control clones carried out in HeLa 
(n = 12) and HCT116 p53-/- (n = 6) cells were done blindly; in addition, at least 3 
independent experiments were conducted per assay. Retrotransposition assays were 
carried out as previously described (Heras et al, 2013; Wei et al, 2000). Briefly, cells were 
plated in 6-well dishes (for retrotransposition and toxicity assays, Corning); when indicated, 
cells were plated in 10-cm plates (for toxicity assays, Corning). For assays employing 
human LINE-1-based constructs (plasmid JM101/L1.3 and mutants, JJ101/L1.3 and 
mutants, and pXY014 and mutants), approximately 2x104 cells were plated per well in a 6-
well dish; when employing zebrafish LINEs (plasmid Zfl2-2mneoI) and LTR-
retrotransposons (plasmid pCMVMusD-6neoTNF), approximately 4x104 cells were plated 
per well in a 6-well dish; in toxicity assays (plasmids pU6ineo or pcDNA6.1), approximately 
1x104 cells were plated per well in a 6-well dish; in some toxicity assays, approximately 
4x104 cells were plated in 10-cm plates. Eighteen hours after plating, DNA transfections 
were carried out using FuGene 6 transfection reagent (Promega) and Opti-MEM (Life 
Technologies) following the protocol provided by the manufacturer (for a six well plate: 3 μl 
of FuGene and 97 μl of Opti-MEM and 1 μg of DNA transfected; for a 10-cm plate: 12 μl of 
FuGene and 388 μl of Opti-MEM and 4 μg of DNA transfected). The day after transfection, 
media was replaced with fresh media. Luciferase-based retrotransposition assays were 
analysed 96 h post-transfection using the Dual-Glo® luciferase assay system (Promega) 
following the protocol provided by the manufacturer. When G418 selection was applied 
(mneoI containing plasmids), cells were subjected to selection with 400 μg/ml G418 (Life 
Technologies) starting approximately 72 h post-transfection; when blasticidin S selection 
was applied (mblastI containing plasmids), cells were subjected to selection with 5 μg/ml 
blasticidin S (Life Technologies) starting approximately 120 h post-transfection; G418 
selection was conducted for 12 days, while blasticidin S selection was carried out for 7 
days. After selection, antibiotic resistant colonies were fixed with 2% 
paraformaldehyde/0.4% glutaraldehyde, and stained with 0.1% crystal violet solution as 
described (Moran et al, 1996; Wei et al, 2000). In all experiments, a co-transfection with 
plasmid pCEP-EGFP was carried out in parallel to control for Transfection Efficiency (TE); 
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co-transfected cells were harvested 72h post-transfection and we used FACS to determine 
the percentage of EGFP-expressing cells. In the overexpression experiments, to control 
for toxicity and colony forming capacity, cells were transfected in parallel with the indicated 
toxicity vector (either pU6i-NEO or pcDNA6.1) and colony numbers used for additional 
normalization as described (Kopera et al, 2016). Selection, fixation, and staining were 
conducted as described above. 
 
Transposition Assays  
To assay SB transposition in HeLa and U2OS parental cells, and derived RNASEH2A-KO 
and control clones, approximately 1x105 cells were plated per well in a 6-well dish. Eighteen 
hours after plating, DNA transfections were carried out using FuGene 6 and Opti-MEM 
following the protocol provided by the manufacturer (see above). Cells were transfected 
with 1 μg of plasmid pT2neo or co-transfected with 1 μg of plasmid pT2neo and 0.5 μg of 
plasmid pCMV-SB100x per well. Seventy-two hours after transfection, cells were 
trypsinised and counted; next, 10% of the transfected cells were plated on a 10-cm plate 
and G418 selection started forty-eight hours later (using 400 μg/ml). G418 selection was 
conducted for 10 days, and G418-resistant colonies were fixed with 2% 
paraformaldehyde/0.4% glutaraldehyde, and stained with 0.1% crystal violet solution. As 
in retrotransposition experiments, a co-transfection with plasmid pCEP-EGFP was carried 
out in parallel to control for TE differences.  
 
PCR-based mutation analyses 
To test whether RNase H2 deficiency caused increased mutation rates in de novo inserted 
L1-sequences, we used a previously described assay (Bogerd et al, 2006). Briefly, parental 
HeLa, HeLa RNASEH2A-KO1 and KO2 cells were plated (1x105 cells per well in a 6-well 
dish) and 18 h later transfected with 1 μg of plasmid JM101/L1.3 or with plasmid 
JM101/L1.3-D702A as a control, using the conditions described above. Forty-eight (2 d) 
and one hundred and twenty hours (5 d) after transfection, genomic DNA (gDNA) was 
isolated from transfected cells, digested with SwaI (NEB; there is a single SwaI site within 
the intron of the mneoI retrotransposition indicator cassette) and used as template in PCR 
reactions using primers NEO437s (5’GAGCCCCTGATGCTCTTCGTCC) and NEO1808as 
(5’ CATTGAACAAGATGGATTGCACGC), that flank the engineered intron in mneoI. PCR 
reactions were carried in 25 μl using KAPA Taq ReadyMIx PCR and 0.4 μM of each primer. 
DNA-free water (Gibco) was included as a negative control in all assays, as well as PCR 
reactions conducted on gDNA isolated from naïve HeLa, and gDNA from naïve HeLa 
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digested with SwaI. PCR conditions for NEO amplification were as follows: 1x (95ºC, 3 
min); 40x (15s, 95ºC; 15s, 60ºC; 30s, 72ºC) 1x, (72ºC, 1 min). PCR products were resolved 
on 1.5% agarose gels, amplified products excised, purified, and cloned in pGEMT-Easy 
(Promega). We sequence 15-20 clones per sample using M13FWD primer. 
 
Statistics 
Unless otherwise stated, all statistics were performed using two-sided unpaired t-test 
(parametric) or Mann-Whitney test (non-parametric) comparing replicates as indicated. P 
< 0.05 was considered as statistically significant. 
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Figure Legends 
Figure 1. Reduced LINE-1 retrotransposition in RNase H2 null HeLa cells 
A. Western blot analysis shows absence of RNASEH2A and reduced RNASEH2B and C 
in RNASEH2A-KO clones (KO1-6), compared to parental cells or control clones (C1-5). 
Tubulin was used as a loading control. See also Source Data. 
B. RNase H assay shows absence of activity against single embedded ribonucleotides in 
KO clones, with a smaller, but consistent reduction in all control clones. Activity in parental 
HeLa cells set at 100%. Data points represent the mean of 3 technical replicates for 
individual clones. Lines indicate the mean of 6 biological replicates (C1-6 and KO1-6) ± 
SEM. 
C. High levels of genome embedded ribonucleotides in KO clones. Genomic DNA isolated 
from parental cells, KO and control clones, was RNase H2 treated and separated by 
alkaline gel electrophoresis. Smaller fragments indicate larger numbers of embedded 
ribonucleotides. 
D. Schematic of retrotransposition vector JJ101/L1.3 (see also Figure EV1A). Within L1-
ORF2p, relative positions of EN (endonuclease), RT (Reverse Transcriptase) and C 
(cysteine-rich) domains are indicated. Orange box with backward BLAST label depicts the 
retrotransposition indicator cassette mblastI. 
E. Quantification of L1-WT retrotransposition, normalised to the level in parental cells and 
normalised for transfection efficiency (TE), set to 100% for comparison. Data points 
represent the mean of 3 technical replicates for individual clones. Lines indicate the mean 
of 6 biological replicates (C1-6 and KO1-6) ± SEM (representative of 6 independent 
experiments). Mann Whitney test; **, P < 0.001 
F. Representative retrotransposition assay conducted in parental cells, control clones (C1-
6), and RNASEH2A-KO clones (KO1-6). Cells were transfected with JJ101/L1.3 vectors 
containing an active human LINE-1 (WT-hL1, element L1.3), an EN-mutant LINE-1 (ENm-
hL1, L1.3 D205A) or an RT-mutant LINE-1 (RTm-hL1, L1.3 D702A). 
 
Figure 2. Reduced LINE-1 retrotransposition in RNase H2 null U2OS cells  
A. Western blot analysis shows absence of RNASEH2A and reduced RNASEH2B and C 
in RNASEH2A-KO clones (KO1, KO2), compared to parental cells or a control clone (C1). 
Vinculin was used as a loading control. See also Source data. 
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B. RNase H assay shows absence of activity against single embedded ribonucleotides in 
KO clones, compared to control cells. Activity in parental U2OS cells set at 100%. Mean ± 
SD for 2 independent experiments. 
C. High levels of genome embedded ribonucleotides in U2OS RNASEH2-KO clones. 
Genomic DNA were isolated from parental cells, KO and control clones, RNase H2 treated 
and separated by alkaline gel electrophoresis. Smaller fragments indicate more genome 
embedded ribonucleotides. 
D. Schematic of plasmid JJ101/L1.3 and representative retrotransposition and toxicity 
assays conducted in parental U2OS cells, a control clone (C1), and two RNASEH2A-KO 
clones (KO1 and KO2). Cells were transfected with vectors containing an active human 
LINE-1 (WT-hL1, element L1.3), an RT-mutant (RTm-hL1, L1.3 D702A), or a toxicity control 
vector (CTRL, pcDNA6.1). Quantification of L1-WT retrotransposition, with the level in 
parental cells set to 100% for comparison. Plotted, mean ± SD for 3 technical replicates. 
Indicated is the average of n = 2 controls (parental, C1) and n = 2 (KO1, KO2) ± SD 
(representative of 3 independent experiments). 
 
Figure 3. RNase H2 activity is required for LINE activity but dispensable for LTR-
retroelement and DNA-Transposon activity 
A. Schematic of retrotransposition vectors Zfl2-2mneoI and JM101/L1.3. The relative 
position of the EN domain (endonuclease), RT domain (Reverse Transcriptase) and C 
domain (cysteine-rich), if present, is indicated. The purple box with a backward NEO label 
depicts the retrotransposition indicator cassette mneoI. 
B. Representative retrotransposition assays conducted in parental cells, control (C2), and 
RNASEH2A-KO (KO2) clones. Cells were transfected with vectors containing an active 
human LINE-1 (WT-hL1, element L1.3), an RT-mutant human LINE-1 (RTm-hL1, L1.3 
D702A), or an active zebrafish LINE-2 (WT-zL2, element Zfl2-2). 
C. Quantification of WT-hL1 (circles) and WT-zL2 (squares) retrotransposition in HeLa 
cells, normalised to the level in parental cells (set at 100%). Data points represent the mean 
of 3 technical replicates for individual clones. Lines indicate the mean of 5 biological 
replicates (C2-6 and KO2-6) ± SEM (representative of 3 independent experiments). For 
WT-hL1, in control lines (n = 5) retrotransposition levels averaged 83±2.5%; in null lines (n 
= 5) retrotransposition levels averaged 7±2.3%. Mann Whitney test; **, P < 0.001. 
D. Left, schematic of a neoTNF tagged MusD LTR-retrotransposon. The relative position of 
the gag, pro and pol genes is indicated. The purple box with a backward NEO label depicts 
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the retrotransposition indicator cassette neoTNF. Right, quantification of MusD 
retrotransposition, normalised to the level in parental cells (set at 100%). Data points 
represent the mean of 3 technical replicates for individual clones. Lines indicate the mean 
of 6 biological replicates (C1-6 and KO1-6) ± SEM (representative of 3 independent 
experiments). t- test; ns, P > 0.05. 
E. Left, schematic of the two plasmids used in Sleeping Beauty transposition assays. The 
purple box with a NEO label depicts the neo expression cassette. Underneath, a 
representative result is shown for DNA-Transposition assays (pT2neo + SB100x) or 
controls (only pT2neo). Right, quantification of the SB transposition results (pT2neo + 
SB100x samples), with the level in parental cells set at 100% for comparison. Mean ± SD 
for n = 3 technical replicates (representative of 3 independent experiments). 
 
Figure 4. RNase H2 overexpression increases LINE-1 retrotransposition in HeLa and 
U2OS cells 
A, B. Panels (A) (HeLa cells) and (B) (U2OS cells) follow the same nomenclature. Shown 
is a representative result for retrotransposition and toxicity assays, underneath a schematic 
of the retrotransposition vector JJ101/L1.3 used. Cells were transfected with JJ101/L1.3 
(as indicated: WT-hL1 (L1.3), active human LINE-1; ENm-hL1 (D205A), EN-mutant; RTm-
hL1 (D702A), RT-mutant) or the toxicity control vector (CTRL, pcDNA 6.1), indicated in the 
top), alongside an expression vector for β-arrestin as a negative control (-ve), the three 
RNase H2 subunits (RNase H2, at a 1:1:1 ratio), or a plasmid expressing APOBEC3A as 
a positive control (+ve) known to restrict LINE-1 retrotransposition. Right panel, 
quantification of this retrotransposition assay; with the level in cells co-transfected with β-
arrestin set at 100% for comparison. Values were normalised for transfection efficiency and 
toxicity. Mean ± SD for n = 3 technical replicates (representative of 4 independent 
experiments). Unpaired two-sided t-test; **, P < 0.01; ***, P < 0.001 
 
Figure 5. Complementation of RNASEH2A-KO cells with wildtype, but not separation 
of function RNASEH2A rescues LINE-1 retrotransposition 
A, B. RNase H activity assays against single embedded ribonucleotides using recombinant 
purified proteins (RNASEH2A-WT and RNASEH2A-SoF). Note that only RNASEH2A-WT 
shows activity in this assay. Plotted, mean ± SEM for 3 independent experiments. 
C, D. RNase H activity assays against RNA:DNA heteroduplexes using recombinant 
purified proteins (RNASEH2A-WT and RNASEH2A-SoF). Note that the pattern of products 
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generated by RNASEH2A-SoF is different from the wildtype pattern. Plotted, mean ± SEM 
for 3 independent experiments. 
E. Western blot analysis of RNase H2 expression in RNASEH2A-KO HeLa cells 
complemented with the indicated retroviral vector (EV, empty vector; WT, wildtype 
RNASEH2A; SoF, RNASEH2A-P40D/Y210A; CD, RNASEH2A-D34A/D169A, see main 
text for details). Tubulin was used as a loading control. See also Source Data. 
F. RNase H activity against single embedded ribonucleotides in RNASEH2A-KO cells is 
only rescued by wildtype RNASEH2A (KO1+WT). DRD:DNA heteroduplex (18 bp; 
ribonucleotide-containing strand 3’-labelled) was incubated with increasing amounts of 
whole cell lysate from the indicated cell line, and separated by denaturing PAGE. The graph 
shows mean values ± SEM for 3 independent experiments.  
G. RNase H activity against RNA:DNA heteroduplexes in RNASEH2A-KO cells is rescued 
by wildtype (KO1+WT), not by CD RNASEH2A (KO1+CD) or the empty vector (KO1+EV). 
Note reduced activity and the difference in cleavage pattern produced by SoF RNASEH2A 
(KO1+SoF). RNA:DNA heteroduplex (18 bp; RNA strand 3’-labelled) was incubated with 
increasing amounts of whole cell lysate from the indicated cell line, and separated by 
denaturing PAGE. Plotted, mean ± SEM for 3 independent experiments. 
H. Only wildtype RNASEH2A rescues the LINE-1 retrotransposition defect in RNASEH2A-
KO cells. Left, representative retrotransposition and toxicity assays conducted in the four 
complemented lines. Cells were transfected with vectors containing an active human LINE-
1 (WT-hL1, L1.3), an RT-mutant LINE-1 (RTm-hL1, D702A), or a toxicity control plasmid 
(CTRL, pcDNA 6.1). Right, quantification of L1-WT retrotransposition. For comparison, the 
retrotransposition level in KO1 cells complemented with the empty vector (EV) was set at 
100%. Mean ± SD for n = 3 technical replicates (representative of 6 independent 
experiments). 
 
Figure 6. Cellular RNase H activity against RNA:DNA hybrids is important for L1 
retrotransposition 
A. Increased L1 retrotransposition upon RNase H2 SoF overexpression. Left, 
representative retrotransposition and toxicity assays. HeLa cells were transfected with 
vectors containing an active LINE-1 (WT-hL1, L1.3), alongside an expression vector for β
-arrestin as a negative control (-ve), the three RNase H2 subunits (RNase H2, at a 1:1:1 
ratio; with RNASEH2A-WT or SoF), or a plasmid expressing APOBEC3A as a positive 
control (+ve) known to restrict LINE-1 retrotransposition. Right panel, quantification of this 
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retrotransposition assay; with the level in cells co-transfected with β-arrestin set at 100% 
for comparison. Values were normalised for transfection efficiency and toxicity. Mean ± SD 
for n = 2 technical replicates (representative of 3 independent experiments). Unpaired two-
sided t-test; *, P < 0.05. 
B. RNase H activity against RNA:DNA heteroduplexes in RNASEH2A-KO cells (clones 
KO1 and KO2) is partially rescued by overexpression of human nuclear RNase H1 
(KO1+H1 and KO2+H1 vs KO1+EV and KO2+EV). RNA:DNA heteroduplex (18 bp; RNA 
strand 3’-labelled) were incubated with whole cell lysate and speed of cleavage determined 
using a FRET-based assay. Mean values ± SEM for n = 6 independent experiments. 
C. RNase H activity against single embedded ribonucleotides in RNASEH2A-KO cells 
(clones KO1 and KO2) is not rescued by human RNase H1 (KO1+H1 and KO2+H1 vs 
KO1+EV and KO2+EV). Speed of cleavage of an 18 bp substrate was determined using a 
FRET-based assay. Mean values ± SEM for n = 3 independent experiments. 
D, E. Representative retrotransposition and toxicity assays (D) conducted in the 
RNASEH2-KO clones (KO1 and KO2) complemented with RNASEH2A-WT (+RNASEH2A) 
or with human RNase H1 (+RNASEH1). Cells were transfected with vectors containing an 
active LINE-1 (WT-hL1, L1.3), an RT-mutant LINE-1 (RTm-hL1, D702A), or a toxicity 
control plasmid (CTRL, pcDNA6.1). Quantification of L1-WT retrotransposition (E). For 
comparison, the retrotransposition level in KO1 or KO2 cells was set at 100%. Mean ± SD 
for n = 3 technical replicates (representative of 3 independent experiments). Unpaired two-
sided t-test; **, P < 0.01; ***, P < 0.001 
F. Model for the initial steps of LINE-1 retrotransposition. For details, see main text. 
 
Figure 7. Reduced L1 retrotransposition due to RNase H2 AGS mutations 
A. Western blot analysis of RNase H2 expression in RNASEH2A-KO HeLa cells (KO2) 
complemented with the indicated retroviral vector (EV, empty vector; WT, wildtype 
RNASEH2A; RNASEH2A-G37S; RNASEH2A-E225G). Actin was used as a loading 
control. See also Source Data. 
B. Complementation of RNASEH2A-KO cells with RNASEH2A with AGS mutations (G37S 
and E225G) leads to a small but significant increase in RNase H activity. Mean values ± 
SEM for n = 3 independent experiments. Unpaired two-sided t-test; *, P < 0.05; ns, P > 
0.05. 
C, D. Cells expressing AGS mutant RNase H2 fail to support efficient L1 retrotransposition. 
(C) Representative retrotransposition and toxicity assays conducted in the four 
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complemented lines. Cells were transfected with vectors containing an active human LINE-
1 (WT-hL1, L1.3), an RT-mutant LINE-1 (RTm-hL1, D702A), or a toxicity control plasmid 
(CTRL, pcDNA 6.1).  (D) Quantification of L1-WT retrotransposition in the complemented 
lines. For comparison, the retrotransposition level in KO cells complemented with empty 
vector (EV) was set at 100%. Mean ± SD for n = 3 independent experiments (each 
experiment performed in technical duplicates). Unpaired two-sided t-test; *, P < 0.05; **, P 
< 0.01. 
 
Figure EV1. Reduced LINE-1 retrotransposition in HeLa RNase H2 null cells  
A. Rationale of the retrotransposition assay using mblastI tagged LINE-1s (orange box with 
a backward BLAST label). Schematic of the retrotransposition vector JJ101/L1.3. Within 
the mblastI cassette, the orange arrow and the orange lollipop indicate the presence of a 
promoter and polyadenylation signal respectively. Within L1-ORF2p, the relative position 
of the EN (endonuclease), RT (Reverse Transcriptase) and C (cysteine-rich) domains is 
indicated. SD and SA indicate splice donor and acceptor sites respectively. Upon 
transcription from the CMV promoter located upstream of the L1, the L1 mRNA can be 
spliced by canonical cis-splicing and undergo a round of retrotransposition, resulting in the 
activation of the mblastI reporter and subsequent translation of the blasticidin deaminase 
protein (orange oval with blue BLAST label). In the retrotransposition event shown, the 
black arrows indicate the presence of Target Site Duplications (TSDs) flanking the 5’ 
truncated insertion. 
B. Toxicity controls: similar numbers of blasticidin-resistant colonies were generated for all 
cell lines after transfection with the pcDNA6.1 control vector (schematic). Representative 
results of transfection/selection experiments in parental HeLa cells, control clones (C1-6) 
and KO clones (KO1-6) are shown. 
C. Rationale and schematic of plasmid pYX014. With this plasmid, L1 retrotransposition 
activates Firefly luciferase expression. Briefly, an active human L1 is tagged with a 
luciferase retrotransposition indicator cassette (yellow box with a backward F-luc label). 
Note that the backbone of the plasmid contains an expression cassette for Renilla 
Luciferase, to normalise transfection (big white arrow with R-luc label). The black arrow 
and the black lollipop indicate the presence of a promoter and polyadenylation signal 
respectively in the F-luc cassette. Upon transfection of plasmid pXY014 in cells, 
transcription from the 5´-UTR of L1, the L1 mRNA can be spliced by canonical cis-splicing 
and undergo a round of retrotransposition, resulting in the activation of the firefly luciferase 
reporter and subsequent translation of the F-luciferase protein (yellow star with F-luc label). 
On the other hand, the R-luc cassette on the plasmid can be transcribed and translated 
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into renilla luciferase (white star with R-luc label). In the retrotransposition event shown, 
the black arrows indicate the presence of TSDs flanking the 5’ truncated insertion.  
D. Results from retrotransposition assays conducted in HeLa parental cells, 3 control 
clones (C), and 3 RNASEH2A-KO clones (KO). The retrotransposition level in parental 
cells was set at 100%. Dots represent the mean of 3 technical replicates for individual 
clones. Lines indicate the mean of 3 biological replicates (C2, 4 and 5, and KO2-4) ± SEM 
(representative of 3 independent experiments). t-test, ***, P < 0.001 
E, F. Western blot analysis of L1-ORF1p expression (in triplicate) in parental HeLa cells, a 
control clone (C1) and two KO clonal lines (KO1 and KO2), shows no indirect effect of 
RNase H2 deficiency on L1 expression. Tubulin (E) or β-actin (F) was used as a loading 
control. See also Source Data. 
G. Quantification of Western blot from panel (C) using a LICOR device following 
manufacturer’s instructions.  
	
Figure EV2. RNase H2 activity is required for productive LINE retrotransposition in 
HeLa and U2OS cells  
A. Schematic of retrotransposition vectors Zfl2-2mneoI (zebrafish LINE-2) and JM101/L1.3 
(Human L1.3). The relative position of the EN domain (endonuclease), RT domain 
(Reverse Transcriptase) and C domain (cysteine-rich), if present, is indicated. The purple 
box with a backward NEO label depicts the retrotransposition indicator cassette mneoI. 
Underneath, representative retrotransposition assays conducted in HeLa parental cells, 
control (C2-6), and RNASEH2A-KO (KO2-6) clones (used for quantifications in Figure 3C). 
Cells were transfected with an active human LINE-1 (WT-hL1, element L1.3), an RT-mutant 
human LINE-1 (RTm-hL1, D702A), or an active zebrafish LINE-2 (WT-zL2, element Zfl2-
2) vector. 
B. Representative retrotransposition and toxicity assays conducted in parental U2OS cells, 
a control clone (C1), and two RNASEH2A-KO clones (KO1 and KO2). Cells were 
transfected with an active human LINE-1 (WT-hL1, element L1.3), an RT-mutant human 
LINE-1 (RTm-hL1, D702A), or an active zebrafish LINE-2 (WT-zL2, element Zfl2-2) vector. 
Right, quantification of WT-hL1 (dark grey bars) and WT-zL2 (light grey bars) 
retrotransposition in U2OS cells, with retrotransposition in parental cells for both elements 
set at 100% for comparison. Mean ± SD for n = 3 technical replicates (representative of 3 
independent experiments). 
 
Figure EV3. RNase H2 overexpression facilitates L1 retrotransposition 
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A. Anti-V5 Western blots using lysates of HeLa (left) or U2OS (right) cells transfected with 
the indicated plasmids. Cells were transfected with each independent RNase H2 subunit 
(left side) or co-transfected with the three subunits using two different ratios (1:1:1 or 
14:7:1). β-actin was used as loading control. Asterisks indicate the presence of individual 
subunits. See also Source Data. 
B, C. Schematic of the retrotransposition vector JJ101/L1.3. Underneath, representative 
results from retrotransposition and toxicity assays conducted in HeLa (B) or U2OS (C) 
cells. Cells were transfected with vector JJ101/L1.3 or with the toxicity control vector 
(CTRL, pcDNA6.1) alongside an expression vector for -arrestin (used as a negative 
control, -ve) or for each of the three RNase H2 subunits at the indicated ratio (RNase H2 
14:7:1). Labels indicate if cells were transfected with an active human LINE-1 (WT-hL1, 
element L1.3), an EN-mutant LINE-1 (ENm-hL1, D205A), an RT-mutant LINE-1 (RTm-hL1, 
D702A), or with the toxicity control plasmid (CTRL, pcDNA6.1). Right panels, L1-WT 
retrotransposition quantifications, with the retrotransposition level in cells co-transfected 
with -arrestin (-ve) set at 100% for comparison. Values were normalised for transfection 
efficiency and toxicity. Mean ± SD for n = 3 technical replicates (representative of 4 
independent experiments). Unpaired two-sided t-test; *, P < 0.05 
 
Figure EV4. Complementation of RNASEH2A-KO HeLa cells 
A. Schematic of substrates used in RNase H activity assays. These assays either use an 
18-bp RNA:DNA hybrid (left), or a short dsDNA containing a single embedded 
ribonucleotide (DRD:DNA). RNASEH2A-WT can cleave both with high efficiency (++++), 
whereas RNASEH2A-CD (with D34A and D169A mutations) cannot cleave either (-). The 
separation of function mutant (SoF, with P40D and Y210A mutations) retains some activity 
against RNA:DNA heteroduplexes (++), but has virtually no activity against single 
embedded ribonucleotides (-).  
B. RNase H2 SoF has reduced activity against RNA:DNA heteroduplexes and does not 
fully process the hybrid, even at high concentration and/or long incubation times. RNase H 
activity was measured using the 18-bp RNA:DNA substrate, separating products by 
denaturing PAGE after cleavage with RNase H2. WT, SoF and CD RNase H2 were used 
at 0.25 nM for 4 h (left) or 2.0 nM for 2 h (right). Note, the different pattern of products 
generated for SoF and WT. 
C. As expected, the high levels of genome embedded ribonucleotides in RNASEH2A-KO 
cells is rescued only by complementation with wildtype RNASEH2A (+WT), not by SoF 
RNASEH2A (+SoF), CD RNASEH2A-A (+CD) or the empty vector (+EV). Genomic DNA 
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was isolated from parental cells, a control clone (C1) and the four complemented cell lines 
(+EV, +WT, +SoF and +CD), RNase H2 treated and separated by alkaline gel 
electrophoresis. Smaller fragments indicate larger numbers of embedded ribonucleotides.  
D-G. Representative gels (used for quantifications in Figure 5F and G) with results from 
RNase H activity against single embedded ribonucleotides (D and E) and activity against 
RNA:DNA heteroduplexes (F and G) assays conducted with lysates from the indicated cell 
lines. Because RNase H1 is expressed in all of these cells, activity measured against 
RNA:DNA heteroduplex substrate in RNASEH2A-KO cell lysates is not completely absent. 
In addition, it is likely that other nucleases present in the cell lysate act (non-specifically) 
on the substrate, causing further background activity on both substrates. 
H. Wildtype RNASEH2A rescues the LINE-1 retrotransposition defect in RNASEH2A-KO2 
cells. Representative retrotransposition and toxicity assays conducted in RNASEH2A-KO2 
cells and RNASEH2A-KO2 complemented with wildtype RNASEH2A (+WT). Cells were 
transfected with an active human LINE-1 (WT-hL1, element L1.3), an RT-mutant LINE-1 
(RTm-hL1, D702A), or a toxicity control plasmid (CTRL, pcDNA6.1). Right panel, 
quantification of L1-WT retrotransposition. For comparison, the retrotransposition level in 
KO2 cells was set at 100%. Mean ± SD for n = 3 technical replicates (representative of 3 
independent experiments). 
I. RNase H2 SoF has reduced RNA:DNA heteroduplex substrate affinity. Initial substrate 
conversion rates (Vi) by 0.1 nM recombinant RNase H2 were measured at different 18-mer 
RNA:DNA substrate concentrations. Mean ± SEM for n = 3 independent experiments. Km 
and kcat ± SEM were calculated in GraphPad Prism 5.04, using non-linear regression. 
Change for SoF compared to WT indicated between brackets. 
 
Figure EV5. Reduced enzyme activity for recombinant RNase H2 carrying AGS 
disease mutations. 
A, B. RNase H activity assays (against 18-mer RNA:DNA heteroduplex) using the indicated 
recombinant purified proteins. Wild type or mutant recombinant RNase H2 (RNASEH2A-
P40D/Y210A, RNASEH2A-G37S, RNASEH2A-E225G, RNASEH2B-A177T and 
RNASEH2C-R69W) were tested using the indicated protein concentration. As previously 
shown (Reijns et al, 2011), the A177T mutation had limited impact on enzyme activity; 
whereas the G37S, E225G and R69W mutations all caused a substantial reduction in 
RNase H2 activity. Note that only RNase H2-SoF (RNASEH2A-P40D/Y210A) generates 
an altered cleavage pattern. Shown are representative results from 3 independent 
experiments.  
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Appendix Figure S1. Reduced LINE-1 retrotransposition in RNase H2 null 
HCT116 p53-/- cells  
A. Western blot analysis shows absence of RNASEH2A and reduced RNASEH2B 
and C in RNASEH2A-KO clones (KO1, KO2), compared to control clones (C1-4). 
Tubulin was used as a loading control. See also Source data. 
B. RNase H assay shows absence of activity against single embedded 
ribonucleotides in KO clones, compared to control cells. Mean ± SD for n= 3 
independent experiments. 
C. High levels of genome embedded ribonucleotides in HCT116 p53-/- RNASEH2-KO 
clones. Genomic DNA was isolated from control and KO clones, RNase H2 treated 
and separated by alkaline gel electrophoresis. Smaller fragments indicate more 
genome embedded ribonucleotides. 
D. Schematic of plasmid JJ101/L1.3, and representative retrotransposition and 
toxicity assays conducted in HCT116 p53-/- control clones (C1-4), and in two 
RNASEH2A-KO clones (KO1 and KO2). Cells were transfected with active human 
LINE-1 (WT-hL1, element L1.3), RT-mutant LINE-1 (RTm-hL1, D702A), or a toxicity 
control vector (CTRL, pcDNA6.1).  
E. Quantification of L1-WT retrotransposition, with average retrotransposition in 
control cells set to 100% for comparison, shows reduced activity in RNase H2 null 
cells. Dots represent the mean of 3 technical replicates for individual clones. Lines 
indicate the mean of n=4 biological replicates for controls (C1-4) and n=2 for KO 
clones (KO1, 2) ± SEM (representative of 5 independent experiments). t-test, **, 
p<0.01 
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Appendix Figure S2. RNase H2 activity is dispensable for LTR-retroelement 
and DNA-Transposon activity 
A. Schematic of a neoTNF tagged MusD mouse LTR-retrotransposon. The relative 
position of the gag, pro and pol genes is indicated. The purple box with a backward 
NEO label depicts the retrotransposition indicator cassette neoTNF, and the purple 
arrow and lollipop indicate the presence of a promoter and polyadenylation signal 
respectively. Upon transcription from the CMV promoter located upstream of the 
MusD element, this mRNA can be spliced by canonical cis-splicing and undergo a 
round of LTR-retrotransposition, resulting in the activation of the neoTNF reporter and 
subsequent translation of the neomycin phosphotransferase protein (purple oval with 
white NEO label). In the LTR-retrotransposition event shown in the bottom, the black 
arrows indicate the presence of TSDs flanking the MusD insertion.   
B. Representative results of LTR-retrotransposition assays in HeLa control (C1-6) 
and RNASEH2A KO (KO1-6) clones. Labels indicate if cells were transfected with a 
tagged active mouse MusD element (MusD) or with the toxicity control plasmid 
(pU6ineo). 
C. Quantification of LTR-retrotransposition assays in U2OS control (C1) and 
RNASEH2A-KO1 clones. Mean ± SD for n=3 technical replicates (representative of 3 
independent experiments). 
D. Schematic of the two plasmids used in the Sleeping Beauty transposition assay. 
The purple box with a NEO label depicts the neo expression cassette. Underneath, 
quantification of SB assays in U2OS cells. Mean ± SD for n=2 technical replicates 
(representative of 3 independent experiments). 
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Appendix Figure S3. No increased mutation rate in de novo LINE-1 insertions 
in RNase H2 null cells 
A. Schematic of retrotransposition assay using plasmid JM101/L1.3. Red arrows 
indicate primers, flanking the engineered intron present in mneoI, used in the PCR 
assay. Note the SwaI site in the engineered mneoI intron (dashed vertical line), 
which, when cut, prevents amplification of intron-containing PCR product.  
B. Time line of the mutation detection assay.  
C. PCR products separated by agarose gel electrophoresis. Products amplified using 
DNA isolated from WT, KO1 and KO2 cell lines after 2 or 5 days, as indicated; 
genomic DNA digested with SwaI prior to PCR (see A). C(-), negative control without 
template DNA. M, marker (1-Kb ladder, molecular weight standard). Arrow indicates 
the expected PCR product; * indicates product resulting from the use of cryptic splice 
sites in the Neo coding sequence.  
D. Schematic of the spliced mneoI cassette, where the presence of tandem repeats 
are indicated using yellow boxes. The green box (labelled Alternative Intron) 
indicates the relative position of the cryptic intron. Red arrows indicate the relative 
position of primers used for PCR. 
E. Mutation rate is not increased in RNase H2 deficient cells (-) when compared to 
RNase H2 proficient control cells (+). 
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Appendix Figure S4. Increased RNase H activity against RNA:DNA 
heteroduplexes in RNASEH2A-KO HeLa cells complemented with human 
RNase H1 
A, B. RNase H activity assays conducted on RNASEH2A-KO cells (A, KO1; B, KO2) 
complemented with human nuclear RNASEH1 (+RNASEH1) or with empty vector 
(+EV). RNase H activity was measured using the 18-bp RNA:DNA substrate, 
separating products by denaturing PAGE after incubation with lysates from the 
indicated cell lines using increasing amounts of total protein. Left panels, 
representative gels. Right panels, quantifications showing mean ± SEM of n=4 (KO1) 
or n=3 (KO2) independent experiments. Mean for n=3 independent experiments. 
Two-way ANOVA with post-hoc Bonferroni multiple comparison test shows 
significant increase in activity against RNA:DNA heteroduplexes in KO+RNASEH1 
compared to KO+EV cells. ***, p<0.001; ****, p<0.0001 
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